Blueprint Medicines has been a possible buyout target for large pharma companies thanks to its attractive precision cancer therapy focus. But some of the Massachusetts biotech’s recent moves suggest ...

An Ayvakit trial win in the rare blood disorder of indolent systemic mastocytosis could be an inflection point for Blueprint Medicines’ commercial business. The company now has positive trial data to ...

Blueprint Medicines (BPMC) has issued an update. At Blueprint Medicines Corporation’s 2024 Annual Meeting, shareholders backed key initiatives, including the adoption of the 2024 Stock Incentive Plan ...

Squarespace wants you to build a website with AI. Its Blueprint AI Builder feature began life as a guided website design system in 2023, but, like many things these days, it was revamped with ...